课题基金 / 基金详情

The BeAMS-50plus Study Benefits and Adverse Effects of Beta-interferon for Multiple Sclerosis patients aged 50 plus

The BeAMS-50plus Study Benefits and Adverse Effects of Beta-interferon for Multiple Sclerosis patients aged 50 plus
BeAMS-50plus 研究 β-干扰素对 50 岁以上多发性硬化症患者的益处和副作用
批准号:
243469
负责人:
Tremlett Helen L
金额:
$7.27万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2011
资助国家:
加拿大
项目状态:
已结题
起止时间:
2011-10-01 至 2012-10-01

项目摘要

项目成果

Tremlett Helen L的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Multiple Sclerosis (MS) is a relatively common disease of the brain and spinal cord, leading to disability, severe fatigue, and coordination problems. Canada has some of the world's highest rates, with three more Canadians diagnosed every day. However, li
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Human immunodeficiency virus, antiretroviral drugs and multiple sclerosis risk (HIV-MS)
  • 批准号:
    385764
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2018
  • 负责人:
    Tremlett Helen L
  • 依托单位:
Prescription Drug Safety and Effectiveness in Multiple Sclerosis [DRUMS]: a population-based, multi-province platform for comprehensive pharmacovigilance
  • 批准号:
    368806
  • 项目类别:
    Operating Grants
  • 资助金额:
    $88.89万
  • 财政年份:
    2017
  • 负责人:
    Tremlett Helen L
  • 依托单位:
Disease-modifying Drug Safety and Effectiveness in Multiple Sclerosis [DRUMS]
  • 批准号:
    367789
  • 项目类别:
    Operating Grants
  • 资助金额:
    $101.65万
  • 财政年份:
    2017
  • 负责人:
    Tremlett Helen L
  • 依托单位:
Canada Research Chair Tier 2
  • 批准号:
    335775
  • 项目类别:
  • 资助金额:
    $36.43万
  • 财政年份:
    2015
  • 负责人:
    Tremlett Helen L
  • 依托单位:
海外基金